With high response rates approaching nearly 100% in relapsed and/or refractory HCL patients, treatment with BRAF and MEK inhibitors underscores the susceptibility of HCL cells when constitutive BRAF signaling is abrogated. This evidence concerns the gene BRAF and hairy cell leukemia.